The development of assays to successfully detect the IDH mutant genotype has been challenging, particularly due to the heterogeneity of gliomas [134,135,136] and heterozygosity of IDH mutations [137], which collectively lend to a low copy number within a sample. This evidence concerns the gene IDH1 and central nervous system cancer.